NSCLC Survival Rises with Checkpoint Blocker Add-On

(MedPage Today) -- Atezolizumab plus standard therapy also slows disease progression
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news

Related Links:

In this study, miR-448 was expressed higher in NSCLC tissues (P 
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
In this study, we tested the ability of parthenolide to inhibit the proliferating effect of nicotine in lung cancer cell lines. MTT assay was used to measure cell survival of A549 and H526 cells treated with nicotine, parthenolide, and their combination. Angiogenesis inhibition was measured using VEGF detection kit and apoptosis induction was evaluated by measuring caspase-3 activity. Real time PCR assay was used to detect the change in expression of several genes associated with cell proliferation and apoptosis (CASP3, CASP7, CASP8, CASP9, P53, GADD45, BAX, BIM, Bcl-2, TOPO I, and TOPO II). Parthenolide inhibited lung can...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Julie Westerlin Kjeldsen, Trine Zeeberg Iversen, Lotte Engell-Noerregaard, Anders Mellemgaard, Mads Hald Andersen, Inge Marie Svane
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Authors: Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C Abstract Use of epidermal growth factor receptor (EGFR) inhibitors represented by gefitinib and erlotinib has become the standard of treatment for non-small-cell lung cancers (NSCLCs) with activating EGFR mutations. However, the majority of NSCLCs, which overexpress EGFR without such mutations, are resistant to EGFR inhibitors, and the mechanism(s) behind such primary resistance of NSCLCs without activating EGFR mutations to EGFR inhibitors still remains poorly understood. Here in this study, we sho...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In conclusion, these results suggested that abnormal expression of miR‑328 may contribute to cisplatin resistance in NSCLC, and may be considered to be a novel therapeutic target and indicator for the treatment and prognosis of patients with NSCLC treated with cisplatin‑based chemotherapy. PMID: 30221716 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, the present study demonstrated that miR‑3120‑5p promoted NSCLC progression by directly targeting KLF4. PMID: 30221715 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
LIMD2 targeted by miR‑34a promotes the proliferation and invasion of non‑small cell lung cancer cells. Mol Med Rep. 2018 Sep 06;: Authors: Wang F, Li Z, Xu L, Li Y, Li Y, Zhang X, Wang Y, Liu D Abstract A previous study indicated that LIM domain containing 2 (LIMD2) is an oncogene in a variety of human cancers, including breast, bladder and thyroid cancers, and melanoma; however, the role of LIMD2 in non‑small cell lung cancer (NSCLC) remains largely unknown. In the present study, by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis, it was demonstrated that LIMD...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In conclusion, results of the present study demonstrated that LINC00978 exerts an oncogenic role in NSCLC by inhibiting miR‑6754‑5p expression. PMID: 30221669 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Condition:   Adenocarcinoma of Lung Interventions:   Drug: CT-16;   Drug: Avastin Sponsor:   Celltrion Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Non-Small Cell Lung Cancer;   Triple-negative Breast Cancer Intervention:   Biological: PF-06936308 Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Non-Small Cell Lung Cancer | Primary Care